Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.61 |
| ▸ | PPARA | Q07869 | 9/20 | 0.61 |
| ▸ | PPARD | Q03181 | 8/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180559 | 0.83 | PPARG (0.65) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL4414532 | 0.80 | HTR6 (0.41) | PPARGPPARAPPARDMCL1 | |
| SCHEMBL5011220 | 0.78 | PPARG (0.59) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL15157114 | 0.77 | HTR2C (0.57) | PPARGPPARAPPARD | |
| SCHEMBL5009255 | 0.76 | PPARG (0.55) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL5011219 | 0.76 | PPARG (1.00) | PPARGPPARAPPARDMCL1 | |
| SCHEMBL5006765 | 0.75 | PPARG (0.56) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL5009245 | 0.74 | PPARG (0.52) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL5009209 | 0.73 | PPARG (0.54) | PPARGPPARAPPARDMCL1NR1H2 | |
| SCHEMBL5009191 | 0.73 | PPARG (0.54) | PPARGPPARAPPARDMCL1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PPARG 1069/4885PPARA 1122/4885PPARD 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.